the present invention provides methods for preparing the solid pharmaceutical compositions described herein . these methods offer an alternate approach to processing wet granulation based formulations that require a buffer for bioavailability as compared to prior art methods . it has been determined that the order of addition of excipients during the granulation process affects the drug product &# 39 ; s dissolution when stored for stability studies . in another aspect , the invention provides pharmaceutical compositions that may be prepared by such methods , comprising the active ingredients , buffers and additional excipients as described herein . in yet another aspect , the invention provides methods for treating disorders using the pharmaceutical compositions as described herein . the patent and / or scientific literature referred to herein establishes knowledge that is available to those with skill in the art . unless otherwise defined , all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention relates . although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention , the preferred methods and materials are described herein . the issued patents , applications , and references that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference . in the case of inconsistencies , the present disclosure , including definitions , will control . in addition , the materials , methods , and examples are illustrative only and are not intended to be limiting . the term “ active ingredient ” is used herein to mean a component of a pharmaceutical composition that is pharmaceutically or physiologically active . the term “ pharmaceutically acceptable excipient ” is used herein to refer to a material that is compatible with a recipient subject , preferably a mammal , more preferably a human , and is suitable for delivering an active agent to the target site without terminating the activity of the agent . the toxicity or adverse effects , if any , associated with the excipient preferably are commensurate with a reasonable risk / benefit ratio for the intended use of the active ingredient . classes of pharmaceutically acceptable excipients include , but are not limited to , surfactants , binders , disintegrants , lubricants , glidants , fillers , and buffers . the term “ about ” is used herein to mean approximately , in the region of , roughly , or around . when the term “ about ” is used in conjunction with a numerical range , it modifies that range by extending the boundaries above and below the numerical values set forth . in general , the term “ about ” is used herein to modify a numerical value above and below the stated value by a variance of 10 %. as used herein , “ w / w %” is used to mean by weight as a percentage of a total weight that is used as the basis for calculating the weight percentage of an individual component . by way of example , for a bulk composition , the w / w % of an individual component may be calculated as a percentage of the total weight of all of the components of the bulk composition . by way of another example , for a single oral dosage form , the w / w % of an individual component may be calculated as a percentage of the total weight of all of the components of the single oral dosage form . for example , when the single oral dosage form is a coated tablet , the total weight may be the total weight of all the components of the coated tablet including the coating ( s ). alternatively , the total weight may be the total weight of all the components of the tablet not including the coating ( s ) as used herein , the term “ comprises ” means “ includes , but is not limited to .” as used herein , a “ subject ” is preferably a bird or mammal , such as a human , but can also be an animal in need of veterinary treatment , e . g ., domestic animals ( e . g ., dogs , cats , and the like ), farm animals ( e . g ., cows , sheep , fowl , pigs , horses , and the like ) and laboratory animals ( e . g ., rats , mice , guinea pigs , and the like ). as used herein , “ treating ” or “ treatment ” means prevention , partial alleviation , or cure of a disease , disorder or condition . as used herein , “ therapeutically effective amount ” is meant to describe an amount of a compound , composition , medicament or other active ingredient effective in producing the desired therapeutic effect . as used herein , the term “ aurora kinase ” refers to any one of a family of related serine / threonine kinases involved in mitotic progression . a variety of cellular proteins that play a role in cell division are substrates for phosphorylation by aurora kinase enzymes , including , without limitation , histone h3 , p 53 , cenp - a , myosin ii regulatory light chain , protein phosphatase - 1 , tpx - 2 , incenp , survivin , topoisomerase ii alpha , vimentin , mbd - 3 , mgcracgap , desmin , ajuba , xieg5 ( in xenopus ), ndc10p ( in budding yeast ), and d - tacc ( in drosophila ). aurora kinase enzymes also are themselves substrates for autophosphorylation , e . g ., at thr288 . unless otherwise indicated by context , the term “ aurora kinase ” is meant to refer to any aurora kinase protein from any species , including , without limitation , aurora a , aurora b , and aurora c , preferably aurora a or b . preferably , the aurora kinase is a human aurora kinase . the term “ aurora kinase inhibitor ” or “ inhibitor of aurora kinase ” is used to signify a compound having a structure as defined herein , which is capable of interacting with an aurora kinase and inhibiting its enzymatic activity . inhibiting aurora kinase enzymatic activity means reducing the ability of an aurora kinase to phosphorylate a substrate peptide or protein . in various embodiments , such reduction of aurora kinase activity is at least about 50 %, at least about 75 %, at least about 90 %, at least about 95 %, or at least about 99 %. in various embodiments , the concentration of aurora kinase inhibitor required to reduce an aurora kinase enzymatic activity is less than about 1 μm , less than about 500 nm , less than about 100 nm , or less than about 50 nm . in one aspect , the present invention provides methods of preparing a pharmaceutical composition comprising the steps of : ( a - 1 ) wet granulating at least one active ingredient , and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants , binders , and disintegrants in the presence of a suitable solvent to form a wet mixture ; ( a - 2 ) drying the wet mixture from step ( a - 1 ), to form dried granules ; ( a - 3 ) milling the dried granules from step ( a - 2 ), to form milled granules ; and ( a - 4 ) blending the milled granules from step ( a - 3 ) with a buffer and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants , binders , disintegrants , lubricants and glidants ; wherein a filler is added during step ( a - 1 ), during step ( a - 4 ), or during both steps ( a - 1 ) and ( a - 4 ). in a further embodiment , the methods of the invention also comprise the step of ( b - 1 ) loading the resulting mixture from step ( a - 4 ) into a capsule . in another further embodiment , the methods of the invention comprise the step of ( c - 1 ) tabletting the resulting mixture from step ( a - 4 ) to form a tablet . in some embodiments , the methods of the invention comprise adding a lubricant during step ( a - 4 ), and then ( c - 1 ) tabletting the resulting mixture from step ( a - 4 ) to form a tablet . in still a further embodiment , the methods of the invention also comprise the step of ( c - 2 ) coating the tablet resulting from step ( c - 1 ). in some embodiments , the tablets are film - coated , or enterically coated , or both . in some other embodiments , the tablets are film - coated and enterically coated . in a further embodiment , the wet granulating step ( a - 1 ) of the methods of the invention is preceded by step ( a - 0 ) dry blending at least one active ingredient , and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants , binders , disintegrants , and fillers . in some embodiments , step ( a - 4 ) can be performed as a single blending step during which all of the pharmaceutically acceptable excipients are added at one time . in other embodiments , step ( a - 4 ) can be performed as consecutive blending steps during which one pharmaceutically acceptable excipient is added at a time . in still other embodiments , during step ( a4 ), one or more lubricants may be added after all the other pharmaceutically acceptable excipients have been added . the wet granulating step ( a - 1 ) outlined herein can take place in any conventional granulation system or apparatus . examples of such granulation equipment include , but are not limited to , high shear granulators , fluid bed granulators , hot melt granulators , one - pot based granulators , extrusion - based granulators , spheronization - based granulators , and spray drying based granulators . an example of a high shear granulator is diosna p1 - 6 high shear granulator , which is manufactured by diosna dierks & amp ; söhne gmbh , germany . an example of a fluid bed granulator is gpcg - 1 batch fluid bed granulator by glatt air techniques , inc ., usa . in some embodiments , the wet granulating step ( a - 1 ) takes between about 5 minutes to about 60 minutes . in some embodiments at least one active ingredient , and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of surfactants , binders , and disintegrants are mixed together while a suitable solvent is introduced into the granulation system to form a wet mixture . in some other embodiments , the wet granulating step optionally includes additional mixing time after the suitable solvent has been introduced into the granulation system to achieve a desired granulation end point . in some embodiments , the additional mixing time occurs for less than about 15 minutes , or less than about 10 minutes , or less than about 5 minutes . in some embodiments , the additional mixing time occurs for between about 1 minute to about 5 minutes , or between about 1 minute to about 4 minutes , or between about 1 minute to about 3 minutes , or between about 1 minute to about 2 minutes . in some embodiments , the additional mixing time occurs for about 1 minute , or about 2 minutes , or about 3 minutes , or about 4 minutes , or about 5 minutes . in some embodiments , the moisture content during the wet granulating step is between about 15 % w / w to about 45 % w / w , wherein the total weight equals the total amount of material in the wet granulating step . in some embodiments , the moisture content during wet granulating step is between about 20 % w / w to about 40 % w / w , or between about 25 % w / w to about 35 % w / w , or about 30 % w / w , wherein the total weight equals the total amount of material in the wet granulating step . in some other embodiments , the moisture content during the wet granulating step is about 15 % w / w , or about 20 % w / w , or about 25 % w / w , or about 30 % w / w , or about 35 % w / w , or about 40 % w / w , wherein the total weight equals the total amount of material in the wet granulating step . the drying step ( a - 2 ) outlined herein can take place in any conventional drying system or apparatus . examples of such drying equipment include , but are not limited to , fluid bed granulators , and equipment for tray drying , microwave drying , and vacuum drying . an example of a fluid bed granulator is gpcg - 1 , which is manufactured by glatt air techniques , ramsey , n . j . in some embodiments , the drying step takes between about 5 minutes to about 240 minutes . in some other embodiments , the drying step takes between about 60 minutes to about 240 minutes , or about 180 minutes to about 240 minutes . in some embodiments the inlet air temperature is between about 40 ° c . to about 85 ° c . in some other embodiments the inlet air temperature is between about 50 ° c . to about 80 ° c ., or between about 60 ° c . to about 75 ° c ., or about 70 ° c . the milling step ( a - 3 ) outlined herein can take place in any conventional milling system or apparatus . examples of such milling equipment include , but are not limited to , comil ° u3 ( quadro engineering lp , waterloo , on , canada ), fitzmill ® ( fitzpatrick co ., elmhurst , ill .) and equipment for screening using sieves . in some embodiments , the milling step takes between about 2 minutes to about 60 minutes . the blending step ( a - 4 ) outlined herein can take place in any conventional blender such as v - blenders , intermediate bulk containers ( ibc ), drum blenders , tote blenders , cross - flow blenders , and other conventional blenders . an example of a conventional blender is a pk blender , which is manufactured by patterson - kelley co ., east stroudsburg , pa . in some embodiments , the blending step takes between about 5 minutes to about 120 minutes . in some embodiments , the blending speed is between about 10 rpm to about 60 rpm . the dry blending step ( a - 0 ) outlined herein can take place in any conventional blender such as v - blenders , intermediate bulk containers ( ibc ), drum blenders , tote blenders , cross - flow blenders , and other conventional blenders . an example of a conventional blender is a pk blender , which is manufactured by patterson - kelley co ., east stroudsburg , pa . in some embodiments , the blending step takes between about 5 minutes to about 120 minutes . in some embodiments , the blending speed is between about 10 rpm to about 60 rpm . the capsule loading step ( b - 1 ) outlined herein can take place in any conventional capsule filling system or apparatus . in some embodiments , the capsule filling system is semi - automated , and can handle small batch sizes . an example of such a capsule filling system is sold as in - cap ( isopak limited , lincolnshire , stamford , united kingdom ). in some embodiments , the capsule filling system is manual . an example of such a capsule filling apparatus is sold as profill 100 ( torpac , inc ., fairfield , n . j ., usa ). an example of a commerical scale encapsulator is a zanasi 70c , an intermittent motion capsule filler , which is manufactured by i . m . a . industria macchine automatiche s . p . a ., castenaso , italy . the tabletting step ( c - 1 ) outlined herein can take place in any conventional tablet press . an example of tabletting equipment is the piccola plc 8 station pk blender , which is manufactured by smi inc , lebanon , n . j . in some embodiments , the tabletting speed is between about 10 rpm to about 100 rpm . the coating step ( c - 2 ) outlined herein can take place in any conventional tablet coating system . an example of conventional tablet coating equipment is sold as labcoat i ( o &# 39 ; hara technologies , inc , richmond hill , on , canada ). in some embodiments , the coating speed is between about 10 rpm to about 100 rpm . in some embodiments , the coating spray rate is between about 5 g / minute to about 100 g / minute . suitable fillers include , but are not limited to , lactose , microcrystalline cellulose , mannitol , ethyl cellulose , sorbitol , starch , sucrose , calcium phosphate , powdered cellulose , silicified microcrystalline cellulose , isomalt , and mixtures thereof . in some embodiments , the filler is silicified microcrystalline cellulose , microcrystalline cellulose , or mixtures thereof . in some other embodiments , the filler is microcrystalline cellulose . suitable surfactants include , but are not limited to , sodium lauryl sulfate , sodium dodecyl sulfate , polysorbates ( such as tween 20 and tween 80 ), poloxamers ( such as poloxamer 335 and poloxamer 407 ), glyceryl monooleate , and mixtures thereof . in some embodiments , the surfactant is sodium lauryl sulfate , sodium dodecyl sulfate , or mixtures thereof . in some embodiments , the surfactant is sodium lauryl sulfate . suitable binders include , but are not limited to , polyvinylpyrrolidone , ethyl cellulose , maltose sodium alginate , hydroxypropyl methylcellulose ( hpmc ), stearic acid , pregelatinized starch , and mixtures thereof . in some embodiments , the binder is hpmc , polyvinylpyrrolidone , or mixtures thereof . in other embodiments , the binder is polyvinylpyrrolidone . suitable disintegrants include , but are not limited to , colloidal silicon dioxide , powdered cellulose , calcium silicate , crospovidone , calcium alginate , methyl cellulose , chitosan , carboxy methyl cellulose , croscarmellose sodium , carboxymethyl starch , sodium alginate , sodium starch glycolate , pregelatinized starch , and mixtures thereof . in some embodiments , the disintegrant is croscarmellose sodium , crospovidone , or mixtures thereof . in other embodiments , the disintegrant is croscarmellose sodium . suitable lubricants include , but are not limited to , talc , magnesium stearate , sodium stearyl fumarate , glyceryl behenate , hydrogenated vegetable oil , zinc stearate , calcium stearate , sucrose stearate , polyvinyl alcohol , magnesium lauryl sulfate , and mixtures thereof . in some embodiments , the lubricant is magnesium stearate , sodium stearyl fumarate , or mixtures thereof . in other embodiments , the lubricant is sodium stearyl fumarate . suitable glidants include , but are not limited to , silicon dioxide , colloidal silicon dioxide , tribasic calcium phosphate , magnesium stearate , magnesium trisilicate , powdered cellulose , talc , starch , and mixtures thereof . in some embodiments , the glidant is talc , colloidal silicon dioxide , or mixtures thereof . in other embodiments , the glidant is colloidal silicon dioxide . suitable solvents for the wet granulating step of ( a - 1 ) include , but are not limited to , water , ethanol , acetone , and mixtures thereof . the methods of the invention can be used for preparation of solid pharmaceutical compositions comprising any active ingredient suitable for formulating in solid form with a buffer . persons having ordinary skill in the art will recognize that an active ingredient having a basic moiety would be best formulated with an acidic buffer , and that an active ingredient having a acidic moiety would be best formulated with a basic buffer . thus , buffers suitable for use in the present invention include both acidic and basic buffers . for example , in some embodiments , an aqueous solution of the buffer has a ph of less than about 7 . 0 . in other embodiments , an aqueous solution of the buffer has a ph of at least about 7 . 0 . examples of such buffers are known to persons having ordinary skill in the art and may be found in the handbook of pharmaceutical excipients ( 5 th edition ), apha publications . in some embodiments , an aqueous solution of the buffer has a ph of less than about 7 . 0 . in some other embodiments , an aqueous solution of the buffer has a ph of between about 1 . 0 to about 6 . 0 , or between about 2 . 0 to about 6 . 0 , or between about 3 . 0 to about 6 . 0 , or between about 4 . 0 to about 6 . 0 , or between about 5 . 0 to about 6 . 0 . suitable buffers having a ph of less than about 7 . 0 in aqueous solution include , but are not limited to , disodium citrate , trisodium citrate , sodium acetate , monopotassium phosphate , monosodium phosphate , and mixtures thereof . in some embodiments , an aqueous solution of the buffer has a ph of at least about 7 . 0 . in some other embodiments , an aqueous solution of the buffer has a ph of between about 8 . 0 to about 13 . 0 , or between about 8 . 0 to about 12 . 0 , or between about 8 . 0 to about 11 . 0 , or between about 8 . 0 to about 10 . 0 , or between about 8 . 0 to about 9 . 0 . suitable buffers having a ph of at least about 7 . 0 in aqueous solution include , but are not limited to , sodium bicarbonate , disodium phosphate , dipotassium phosphate , potassium bicarbonate , sodium carbonate , potassium carbonate , and mixtures thereof . in some embodiments , the buffer is sodium bicarbonate , sodium carbonate , or mixtures thereof . in other embodiments , the buffer is sodium bicarbonate . in some embodiments , the active ingredient contains an acid moiety . in some other embodiments , the active ingredient is a compound of formula ( a ): r f1 is hydrogen , or r f2 and r f2 together form a bond ; r f2 is hydrogen , or r f2 forms a bond with either r f1 or r x ; each of r x and r y independently is hydrogen , fluoro , or an optionally substituted c 1 - 6 aliphatic ; or r x and r y , taken together with the carbon atom to which they are attached , form an optionally substituted 3 - to 6 - membered cycloaliphatic ring ; or r x and r f2 together form a bond ; g is hydrogen , an optionally substituted aliphatic or ring b when r f1 is hydrogen ; and g is hydrogen , — oqr 5 , — n ( r 4 ) 2 , — sr 5 , an optionally substituted aliphatic , or ring b when r f1 and r f2 together form a bond ; ring a is a substituted or unsubstituted 5 - or 6 - membered aryl , heteroaryl , cycloaliphatic , or heterocyclyl ring ; ring b is a substituted or unsubstituted aryl , heteroaryl , heterocyclyl , or cycloaliphatic ring ; ring c is a substituted or unsubstituted aryl , heteroaryl , heterocyclyl , or cycloaliphatic ring ; r a is hydrogen , — c ( o ) r 1 , — co 2 r 1 , — so 2 r 1 , or a c 1 - 3 aliphatic having 0 - 2 substituents independently selected from r 3 or r 7 ; r e is hydrogen , — or 5 , — n ( r 4 ) 2 , — sr 5 , — nr 4 c ( o ) r 5 , — nr 4 c ( o ) n ( r 4 ) 2 , — nr 4 co 2 r 6 , — n ( r 4 ) so 2 r 6 , — n ( r 4 ) so 2 n ( r 4 ) 2 , or a c 1 - 3 aliphatic optionally substituted with r 3 or r 7 ; r 1 is c 1 - 6 aliphatic or an optionally substituted aryl , heteroaryl , or heterocyclyl group ; each r 3 independently is selected from the group consisting of - halo , — oh , — o ( c 1 - 3 alkyl ), — cn , — n ( r 4 ) 2 , — c ( o )( c 1 - 3 alkyl ), — co 2 h , — co 2 ( c 1 - 3 alkyl ), — c ( o ) nh 2 , and — c ( o ) nh ( c 1 - 3 alkyl ); each r 4 independently is hydrogen or an optionally substituted aliphatic , aryl , heteroaryl , or heterocyclyl group ; or two r 4 on the same nitrogen atom , taken together with the nitrogen atom , form an optionally substituted 5 - to 6 - membered heteroaryl or 4 - to 8 - membered heterocyclyl ring having , in addition to the nitrogen atom , 0 - 2 ring heteroatoms selected from n , o , and s ; each r 5 independently is hydrogen or an optionally substituted aliphatic , aryl , heteroaryl , or heterocyclyl group ; each r 6 independently is an optionally substituted aliphatic or aryl group ; each r 7 independently is an optionally substituted aryl , heterocyclyl , or heteroaryl group . in still a further embodiment , the active ingredient is a compound of formula ( i ): r a is selected from the group consisting of c 1 - 3 aliphatic , c 1 - 3 fluoroaliphatic , — r 1 , - t - r 1 , — r 2 , and - t - r 2 ; t is a c 1 - 3 alkylene chain optionally substituted with fluoro ; r 1 is an optionally substituted aryl , heteroaryl , or heterocyclyl group ; r 2 is selected from the group consisting of halo , — c ≡ c — r 3 , — ch ═ ch — r 3 , — n ( r 4 ) 2 , and — or 5 ; r 3 is hydrogen or an optionally substituted aliphatic , aryl , heteroaryl , or heterocyclyl group ; each r 4 independently is hydrogen or an optionally substituted aliphatic , aryl , heteroaryl , or heterocyclyl group ; or two r 4 on the same nitrogen atom , taken together with the nitrogen atom form an optionally substituted 5 - to 6 - membered heteroaryl or 4 - to 8 - membered heterocyclyl ring having , in addition to the nitrogen atom , 0 - 2 ring heteroatoms selected from n , o , and s ; r 5 is hydrogen or an optionally substituted aliphatic , aryl , heteroaryl , or heterocyclyl group ; r b is selected from the group consisting of fluoro , chloro , — ch 3 , — cf 3 , — oh , — och 3 , — ocf 3 , — och 2 ch 3 , and — och 2 cf 3 . definitions for the substituent groups of the compounds of formula ( a ) and formula ( i ) can be found in u . s . pat . no . 7 , 572 , 784 and us publication no . 2008 / 0167292 , respectively , hereby incorporated by reference in their entirety . unless otherwise stated , structures depicted herein are also meant to include solvated and hydrated forms of the depicted compounds . also included within the scope of the invention are compositions comprising pharmaceutically acceptable salts of compounds of formula ( a ) or formula ( i ), as well as solvated and hydrated forms of such salts . if pharmaceutically acceptable salts of the compounds of formula ( a ) are utilized in the compositions of the invention , the salts preferably are derived from inorganic or organic acids and bases . for reviews of suitable salts , see , e . g ., berge et al , j . pharm . sci . 66 : 1 - 19 ( 1977 ) and remington : the science and practice of pharmacy , 20th ed ., ed . a . gennaro , lippincott williams & amp ; wilkins , 2000 . nonlimiting examples of suitable acid addition salts include the following : acetate , adipate , alginate , aspartate , benzoate , benzene sulfonate , bisulfate , butyrate , citrate , camphorate , camphor sulfonate , cyclopentanepropionate , digluconate , dodecylsulfate , ethanesulfonate , fumarate , lucoheptanoate , glycerophosphate , hemisulfate , heptanoate , hexanoate , hydrochloride , hydrobromide , hydroiodide , 2 - hydroxyethanesulfonate , lactate , maleate , methanesulfonate , 2 - naphthalenesulfonate , nicotinate , oxalate , pamoate , pectinate , persulfate , 3 - phenyl - propionate , picrate , pivalate , propionate , succinate , tartrate , thiocyanate , tosylate and undecanoate . suitable base addition salts include , without limitation , ammonium salts , alkali metal salts , such as sodium and potassium salts , alkaline earth metal salts , such as calcium and magnesium salts , salts with organic bases , such as dicyclohexylamine , n - methyl - d - glucamine , t - butylamine , ethylene diamine , ethanolamine , and choline , and salts with amino acids such as arginine , lysine , and so forth . for example , compounds of formula ( a ), wherein ring c is substituted with — co 2 h may be formulated as a corresponding base addition salt , e . g ., a corresponding sodium salt . if a pharmaceutically acceptable salts of the compounds of formula ( i ) are utilized in the compositions of the invention , the salts preferably are base addition salts . suitable base addition salts are as described above for the compounds of formula ( a ). in some embodiments , the active ingredient is a compound of formula ( i ), or a sodium or potassium salt thereof . in some embodiments , the active ingredient is a crystalline form of a compound of formula ( a ) or formula ( i ). in some other embodiments , the active ingredient is a crystalline form of a pharmaceutically acceptable salt of a compound of formula ( a ) or formula ( i ). some examples of pharmaceutically acceptable salts of the compounds of formula ( a ) or formula ( i ) and crystalline forms thereof can be found in u . s . pat . no . 7 , 572 , 784 , us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . in still a further embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ), or a crystalline form thereof . in another embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) monohydrate . in another embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) polymorph form 2 , as described in us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . suitable materials that may be used to film - coat the tablets in step ( c - 2 ) include , but are not limited to , opadry ® ( hydroxy propyl methylcellulose peg ) ( colorcon , west point , pa . ), opadry ® h ( polyvinyl alcohol , peg , talc , and titanium dioxide ), opadry ® fx , opadry ® amb , and mixtures thereof . in some embodiments , the film - coat material is opadry ®, opadry ® ii , or mixtures thereof . in other embodiments , the film - coat material is opadry ® ii . suitable materials that may be used to enterically coat the tablets in step ( c - 2 ) include , but are not limited to , acryl - eze ® ( methacrylic acid copolymer , talc , sls , titanium dioxide , sodium bicarbonate , silica , triethyl citrate ) ( colorcon , west point , pa . ), cellulose acetate phthalate ( cap ), methyl acrylate - methacrylic acid copolymers , cellulose acetate succinate , hydroxy propyl methyl cellulose phthalate , hydroxy propyl methyl cellulose acetate succinate ( hypromellose acetate succinate ), polyvinyl acetate phthalate ( pvap ), methyl methacrylate - methacrylic acid copolymers , and mixtures thereof . in some embodiments , the pharmaceutical composition produced after step ( a - 4 ) comprises about 1 % w / w to about 60 % w / w of active ingredient , about 10 % w / w to about 80 % w / w of buffer , and about 10 % w / w to about 80 % w / w of filler . in a further embodiment , the pharmaceutical composition comprises from about 2 % w / w to about 22 % w / w of compound 1 , or a crystalline form thereof . in some embodiments , the pharmaceutical composition comprises from about 3 % w / w to about 15 % w / w of compound 1 , or a crystalline form thereof . in some other embodiments , the pharmaceutical composition comprises about 13 . 6 % w / w of compound 1 , or a crystalline form thereof . in some further embodiments , the pharmaceutical composition comprises a sodium bicarbonate buffer , wherein the sodium bicarbonate buffer is present in the amount from about 10 % w / w to about 60 % w / w . in some embodiments , the sodium bicarbonate buffer is present in the amount from about 20 % w / w to about 40 % w / w . in some other embodiments , the sodium bicarbonate buffer is present in the amount of about 30 % w / w . in still further embodiments , the pharmaceutical composition comprises a microcrystalline cellulose filler , wherein the microcrystalline cellulose filler is present in the amount from about 27 % w / w to about 53 % w / w . in still further embodiments , the bulk composition comprises a sodium stearyl fumarate lubricant , wherein the sodium stearyl fumarate lubricant is present in the amount from about 0 % w / w to about 3 % w / w . in still further embodiments , the pharmaceutical composition produced after step ( a - 4 ) comprises , about 0 % w / w to about 5 % w / w of surfactant , about 0 % w / w to about 20 % w / w of binder , and about 0 % w / w to about 20 % w / w of disintegrant . in still further embodiments , about 30 % to about 70 % of the total amount of the disintegrant is added during step ( a - 1 ) and about 30 % to about 70 % of the total amount of the disintegrant is added during step ( a - 4 ). in another aspect , the present invention provides pharmaceutical compositions . in some embodiments , the pharmaceutical compositions of the invention may be prepared by the methods described herein . in some other embodiments , the pharmaceutical compositions of the invention are bulk compositions . in one embodiment , the bulk composition comprises an active ingredient , a buffer , and a filler . in another embodiment , the bulk composition comprises an active ingredient , a buffer , a filler , and optionally one or more pharmaceutically acceptable excipients independently selected from the group consisting of a lubricant , a surfactant , a binder , a disintegrant , and a glidant . in yet another embodiment , the bulk composition comprises an active ingredient , a buffer , a filler , a lubricant , a surfactant , a binder , and a disintegrant . in one embodiment , the bulk composition comprises about 1 % w / w to about 60 % w / w of active ingredient , about 10 % w / w to about 80 % w / w of buffer , and about 10 % w / w to about 80 % w / w of filler . in another embodiment , the bulk composition comprises about 1 % w / w to about 60 % w / w of active ingredient , about 10 % w / w to about 80 % w / w of buffer , about 10 % w / w to about 80 % w / w of filler , about 0 % w / w to about 5 % w / w of lubricant , about 0 % w / w to about 5 % w / w of surfactant , about 0 % w / w to about 20 % w / w of binder , about 0 % w / w to about 20 % w / w of disintegrant , and about 0 % w / w to about 5 % w / w of a glidant . in another embodiment , the bulk composition comprises about 1 % w / w to about 30 % w / w of active ingredient , about 30 % w / w to about 60 % w / w of buffer , and about 20 % w / w to about 60 % w / w of filler , about 1 % w / w to about 3 % w / w of lubricant , about 0 % w / w to about 3 % w / w of surfactant , about 0 % w / w to about 10 % w / w of binder , about 0 % w / w to about 15 % w / w of disintegrant , and about 0 % w / w to about 2 % w / w of a glidant . in another embodiment , the bulk composition comprises about 10 % w / w to about 16 % w / w of active ingredient , about 28 % w / w to about 40 % w / w of buffer , about 35 % w / w to about 45 % w / w of filler , about 1 % w / w to about 2 % w / w of lubricant , about 1 % w / w to about 2 % w / w of surfactant , about 3 % w / w to about 7 % w / w of binder , about 5 % w / w to about 10 % w / w of disintegrant , and about 0 % w / w to about 2 % w / w of a glidant . in another embodiment , the bulk composition comprises about 13 . 6 % w / w of active ingredient , about 30 . 0 % w / w of buffer , and about 40 . 4 % w / w of filler , about 1 . 0 % w / w of lubricant , about 2 . 0 % w / w of surfactant , about 5 . 0 % w / w of binder , and about 8 . 0 % w / w of disintegrant . suitable fillers include , but are not limited to , lactose , microcrystalline cellulose , mannitol , ethyl cellulose , sorbitol , starch , sucrose , calcium phosphate , powdered cellulose , silicified microcrystalline cellulose , isomalt , and mixtures thereof . in some embodiments , the filler is silicified microcrystalline cellulose , microcrystalline cellulose , or mixtures thereof . in some other embodiments , the filler is microcrystalline cellulose . in some embodiments , the filler is present in an amount from about 10 % w / w to about 80 % w / w . in other embodiments , the filler is present in an amount from about 20 % w / w to about 60 % w / w , or about 25 % w / w to about 55 % w / w , or about 30 % w / w to about 50 % w / w , or about 35 % w / w to about 45 % w / w . in some embodiments , the filler is present in an amount of about 20 % w / w , about 25 % w / w , about 30 % w / w , about 35 % w / w , about 40 % w / w , about 45 % w / w , about 50 % w / w , about 55 % w / w , or about 65 % w / w in some other embodiments , the filler is present in an amount of about 40 . 4 % w / w . in some embodiments , the filler comprises a first filler , which is added during step ( a - 1 ), and a second filler , which is added during step ( a - 4 ), which may be the same or different . in some embodiments , the first filler and the second filler are the same . in some other embodiments , only the first filler is present . in yet some other embodiments , only the second filler is present . in some embodiments , the first filler , and the second filler are each independently selected from the group consisting of lactose , microcrystalline cellulose , mannitol , ethyl cellulose , sorbitol , starch , sucrose , calcium phosphate , powdered cellulose , silicified microcrystalline cellulose , isomalt , and mixtures thereof . in some other embodiments , the first filler , and the second filler are each independently selected from the group consisting of silicified microcrystalline cellulose , microcrystalline cellulose , or mixtures thereof . in certain particular embodiments , the first filler , and the second filler are both microcrystalline cellulose . in some embodiments , the first filler and second filler are each present in the same amount , provided that the total amount of filler is no greater than about 80 % w / w . in other embodiments , the first filler and second filler are each present in different amounts , provided that the total amount of filler is no greater than about 80 % w / w . in some other embodiments , the first filler and second filler are each independently present in an amount from about 0 % w / w to about 80 % w / w , provided that the total amount of filler is no greater than about 80 % w / w . in some other embodiments , the first filler and second filler are each independently present in an amount from about 5 % w / w to about 40 % w / w . in some other embodiments , the first filler and second filler are each independently present in an amount from about 10 % w / w to about 30 % w / w . in some other embodiments , the first filler and second filler are each independently present in an amount of about 10 % w / w , or about 15 % w / w , or about 20 % w / w , or about 25 % w / w , or about 30 %, w / w . in some other embodiments , the first filler and second filler are each independently present in an amount of about 20 % w / w . suitable surfactants include , but are not limited to , sodium lauryl sulfate , sodium dodecyl sulfate , polysorbates ( such as tween 20 and tween 80 ), poloxamers ( such as poloxamer 335 and poloxamer 407 ), glyceryl monooleate , and mixtures thereof . in some embodiments , the surfactant is sodium lauryl sulfate , sodium dodecyl sulfate , or mixtures thereof . in some embodiments , the surfactant is sodium lauryl sulfate . in some embodiments , the surfactant is present in an amount from about 0 % w / w to about 5 % w / w . in other embodiments , the surfactant is present in an amount from about 0 % w / w to about 3 % w / w . in other embodiments , the surfactant is present in an amount from about 1 % w / w to about 2 % w / w . in some other embodiments , the surfactant is present in an amount of about 0 . 5 % w / w , or about 1 % w / w , or about 1 . 5 % w / w , or about 2 % w / w , or about 2 . 5 % w / w , or about 3 % w / w . in some other embodiments , the surfactant is present in an amount of about 2 % w / w . in some embodiments , the surfactant comprises a first surfactant , which is added during step ( a - 1 ), and a second surfactant which is added during step ( a - 4 ), which may be the same or different . in some embodiments , the first surfactant and the second surfactant are the same . in some other embodiments , only the first surfactant is present . in yet some other embodiments , only the second surfactant is present . in some embodiments , the first surfactant , and the second surfactant are each independently selected from the group consisting of sodium lauryl sulfate , sodium dodecyl sulfate , polysorbates ( such as tween 20 and tween 80 ), poloxamers ( such as poloxamer 335 and poloxamer 407 ), glyceryl monooleate , and mixtures thereof . in some embodiments , the surfactant is sodium lauryl sulfate , sodium dodecyl sulfate , or mixtures thereof . in some other embodiments , the first surfactant , and the second surfactant are both sodium lauryl sulfate . in some embodiments , the first surfactant and second surfactant are each present in the same amount , provided that the total amount of surfactant is no greater than about 5 % w / w . in other embodiments , the first surfactant and second surfactant are each present in different amounts , provided that the total amount of surfactant is no greater than about 5 % w / w . in some other embodiments , the first surfactant and second surfactant are each independently present in an amount from about 0 % w / w to about 5 % w / w , provided that the total amount of surfactant is no greater than about 5 % w / w . in some other embodiments , the first surfactant and second surfactant are each independently present in an amount of about 0 . 5 % w / w , or about 1 % w / w , or about 1 . 5 % w / w , or about 2 % w / w , or about 2 . 5 % w / w , or about 3 % w / w , provided that the total amount of surfactant is no greater than about 5 % w / w . in some other embodiments , the first surfactant and second surfactant are each independently present in an amount of about 1 % w / w . suitable binders include , but are not limited to , polyvinylpyrrolidone , ethyl cellulose , maltose sodium alginate , hydroxypropyl methylcellulose ( hpmc ), stearic acid , pregelatinized starch , and mixtures thereof . in some embodiments , the binder is hpmc , polyvinylpyrrolidone , or mixtures thereof . in other embodiments , the binder is polyvinylpyrrolidone . in some embodiments , the binder is present in an amount from about 0 % w / w to about 20 % w / w . in other embodiments , the binder is present in an amount from about 0 % w / w to about 10 % w / w . in some other embodiments , the binder is present in an amount of about 1 % w / w , or about 2 % w / w , or about 3 % w / w , or about 4 % w / w , or about 5 % w / w , or about 6 % w / w , or about 7 % w / w , or about 8 % w / w , or about 9 % w / w , or about 10 % w / w . in some other embodiments , the binder is present in an amount from about 1 % w / w to about 9 % w / w , or about 2 % w / w to about 8 % w / w , or about 3 % w / w to about 7 % w / w , or about 4 % w / w to about 6 % w / w . in some other embodiments , the binder is present in an amount of about 5 %. in some embodiments , the binder comprises a first binder , which is added during step ( a - 1 ), and a second binder which is added during step ( a - 4 ), which may be the same or different . in some embodiments , the first binder and the second binder are the same . in some other embodiments , only the first binder is present . in yet some other embodiments , only the second binder is present . in some embodiments , the first binder , and the second binder are each independently selected from the group consisting of polyvinylpyrrolidone , ethyl cellulose , maltose sodium alginate , hydroxypropyl methylcellulose ( hpmc ), stearic acid , pregelatinized starch , and mixtures thereof . in some other embodiments , the first binder , and the second binder are each independently selected from the group consisting of hpmc , polyvinylpyrrolidone , and mixtures thereof . in certain particular embodiments , the first binder , and the second binder are both polyvinylpyrrolidone . in some embodiments , the first binder and second binder are each present in the same amount , provided that the total amount of binder is no greater than about 20 % w / w . in other embodiments , the first binder and second binder are each present in different amounts , provided that the total amount of binder is no greater than about 20 % w / w . in some other embodiments , the first binder and second binder are each independently present in an amount from about 0 % w / w to about 20 % w / w , provided that the total amount of binder is no greater than about 20 % w / w . in some other embodiments , the first binder and second binder are each independently present in an amount from about 0 % w / w to about 10 % w / w . in some other embodiments , the first binder and second binder are each independently present in an amount from about 0 % w / w to about 5 % w / w . in some other embodiments , the first binder and second binder are each independently present in an amount of about 0 . 5 % w / w , or about 1 % w / w , or about 1 . 5 % w / w , or about 2 % w / w , or about 2 . 5 % w / w , or about 3 % w / w , or about 3 . 5 % w / w , or about 4 % w / w , or about 4 . 5 % w / w , or about 5 % w / w . in some other embodiments , the first binder and second binder are each independently present in an amount of about 2 . 5 % w / w . suitable disintegrants include , but are not limited to , colloidal silicon dioxide , powdered cellulose , calcium silicate , crospovidone , calcium alginate , methyl cellulose , chitosan , carboxy methyl cellulose , croscarmellose sodium , carboxymethyl starch , sodium alginate , sodium starch glycolate , pregelatinized starch , and mixtures thereof . in some embodiments , the disintegrant is croscarmellose sodium , crospovidone , or mixtures thereof . in other embodiments , the disintegrant is croscarmellose sodium . in some embodiments , the disintegrant is present in an amount from about 0 % w / w to about 20 % w / w . in other embodiments , the disintegrant is present in an amount from about 0 % w / w to about 15 % w / w . in some other embodiments the disintegrant is present in an amount from about 1 % w / w to about 14 % w / w , or from about 2 % w / w to about 13 % w / w , or from about 3 % w / w to about 12 % w / w , or from about 4 % w / w to about 11 % w / w , or from about 5 % w / w to about 10 % w / w , or from about 6 % w / w to about 9 % w / w , or from about 7 % w / w to about 8 % w / w . in some other embodiments , the disintegrant is present in an amount of about 4 % w / w , or about 5 % w / w , or about 6 % w / w , or about 7 % w / w , or about 8 % w / w , or about 9 % w / w , or about 10 % w / w , or about 11 % w / w , or about 12 % w / w . in some other embodiments , the disintegrant is present in an amount of about 8 % w / w . in some embodiments , the disintegrant comprises a first disintegrant , which is added during step ( a - 1 ), and a second disintegrant , which is added during step ( a - 4 ), which may be the same or different . in some embodiments , the first disintegrant and the second disintegrant are the same . in some other embodiments , only the first disintegrant is present . in yet some other embodiments , only the second disintegrant is present . in some embodiments , the first disintegrant , and the second disintegrant are each independently selected from the group consisting of colloidal silicon dioxide , powdered cellulose , calcium silicate , crospovidone , calcium alginate , methyl cellulose , chitosan , carboxy methyl cellulose , croscarmellose sodium , carboxymethyl starch , sodium alginate , sodium starch glycolate , pregelatinized starch , and mixtures thereof . in some other embodiments , the first disintegrartt , and the second disintegrant are each independently selected from the group consisting of croscarmellose sodium , crospovidone , and mixtures thereof . in certain particular embodiments , the first disintegrant , and the second disintegrant are both croscarmellose sodium . in some embodiments , the first disintegrant and second disintegrant are each present in the same amount , provided that the total amount of disintegrant is no greater than about 20 % w / w . in other embodiments , the first disintegrant and second disintegrant are each present in different amounts , provided that the total amount of disintegrant is no greater than about 20 % w / w . in some other embodiments , the first disintegrant and second disintegrant are each independently present in an amount from about 0 % w / w to about 20 % w / w , provided that the total amount of disintegrant is no greater than about 20 % w / w . in some other embodiments , the first disintegrant and second disintegrant are each independently present in an amount from about 0 % w / w to about 8 % w / w . in some other embodiments , the first disintegrant and second disintegrant are each independently present in an amount of about 1 % w / w , or about 2 % w / w , or about 3 % w / w , or about 4 % w / w , or about 5 % w / w , or about 6 % w / w , or about 7 % w / w , or about 8 % w / w . in some other embodiments , the first disintegrant and second disintegrant are each independently present in an amount of about 4 % w / w . in some embodiments , the first disintegrant and the second disintegrant each independently comprise about 30 % to about 70 % of the total amount of disintegrant . in other embodiments , the first disintegrant and the second disintegrant each independently comprise about 40 % to about 60 % of the total amount of disintegrant . in some other embodiments , the first disintegrant and the second disintegrant each independently comprise about 40 %, or about 50 %, or about 60 % of the total amount of disintegrant . in some other embodiments , the first disintegrant and the second disintegrant each independently comprise about 50 % of the total amount of disintegrant . suitable lubricants include , but are not limited to , talc , magnesium stearate , sodium stearyl fumarate , glyceryl behenate , hydrogenated vegetable oil , zinc stearate , calcium stearate , sucrose stearate , polyvinyl alcohol , magnesium lauryl sulfate , and mixtures thereof . in some embodiments , the lubricant is magnesium stearate , sodium stearyl fumarate , or mixtures thereof . in other embodiments , the lubricant is sodium stearyl fumarate . in some embodiments the lubricant is present in an amount from about 0 % w / w to about 5 % w / w . in some embodiments the lubricant is present in an amount from about 1 % w / w to about 3 % w / w of lubricant . in some embodiments the lubricant is present in an amount from about 1 % w / w to about 2 % w / w of lubricant . in some other embodiments , the lubricant is present in an amount from about 0 . 5 % w / w to about 4 . 5 % w / w , or from about 0 . 5 % w / w to about 4 % w / w , or from about 0 . 5 % w / w to about 3 . 5 % w / w , or from about 0 . 5 % w / w to about 3 % w / w . in other embodiments , the lubricant is present in an amount from about 0 % w / w to about 3 % w / w . in some other embodiments , the lubricant is present in an amount of about 1 % w / w . suitable glidants include , but are not limited to , silicon dioxide , colloidal silicon dioxide , tribasic calcium phosphate , magnesium stearate , magnesium trisilicate , powdered cellulose , talc , starch , and mixtures thereof . in some embodiments , the glidant is talc , colloidal silicon dioxide , or mixtures thereof . in other embodiments , the glidant is colloidal silicon dioxide . in some embodiments , the glidant is present in an amount from about 0 % w / w to about 5 % w / w . in other embodiments , the glidant is present in an amount from about 0 % w / w to about 2 % w / w . in other embodiments , the glidant is present in an amount from about 0 . 3 % w / w to about 2 % w / w , or about 0 . 8 % w / w to 1 . 5 % w / w . in other embodiments , the glidant is present in an amount of about 0 . 5 % w / w , or about 0 . 7 % w / w , or about 1 % w / w , or about 1 . 2 % w / w , or about 1 . 5 % w / w , or about 1 . 7 % w / w , or about 2 % w / w . in other embodiments , the glidant is present in an amount of about 1 % w / w . suitable solvents for the wet granulating step of ( a - 1 ) include , but are not limited to , water , ethanol , acetone , and mixtures thereof . in some embodiments , the amount of solvent present in the wet granulating step of ( a - 1 ) is from about 10 % w / w to about 50 % w / w . in other embodiments the solvent is present in an amount from about 15 % w / w to about 40 % w / w , or about 28 % w / w . as described above , buffers suitable for use in the present invention include both acidic and basic buffers . for example , in some embodiments , an aqueous solution of the buffer has a ph of less than about 7 . 0 . in other embodiments , an aqueous solution of the buffer has a ph of at least about 7 . 0 . examples of such buffers are known to persons having ordinary skill in the art and may be found in the handbook of pharmaceutical excipients ( 5 th edition ), apha publications . in some embodiments , an aqueous solution of the buffer has a ph of less than about 7 . 0 . in some other embodiments , an aqueous solution of the buffer has a ph of between about 1 . 0 to about 6 . 0 , or between about 2 . 0 to about 6 . 0 , or between about 3 . 0 to about 6 . 0 , or between about 4 . 0 to about 6 . 0 , or between about 5 . 0 to about 6 . 0 . suitable buffers having a ph of less than about 7 . 0 in aqueous solution include , but are not limited to , disodium citrate , trisodium citrate , sodium acetate , monopotassium phosphate , monosodium phosphate , and mixtures thereof . in some embodiments , an aqueous solution of the buffer has a ph of at least about 7 . 0 . in some other embodiments , an aqueous solution of the buffer has a ph of between about 8 . 0 to about 13 . 0 , or between about 8 . 0 to about 12 . 0 , or between about 8 . 0 to about 11 . 0 , or between about 8 . 0 to about 10 . 0 , or between about 8 . 0 to about 9 . 0 . suitable buffers having a ph of at least about 7 . 0 in aqueous solution include , but are not limited to , sodium bicarbonate , disodium phosphate , dipotassium phosphate , potassium bicarbonate , sodium carbonate , potassium carbonate , and mixtures thereof . in some embodiments , the buffer is sodium bicarbonate , sodium carbonate , or mixtures thereof . in other embodiments , the buffer is sodium bicarbonate . in some embodiments , the buffer is present in an amount from about 10 % w / w to about 80 % w / w . in other embodiments , the buffer is present in an amount from about 15 % w / w to about 60 % w / w . in some other embodiments , the buffer is present in an amount from about 20 % w / w to about 55 % w / w , or from about 22 % w / w to about 50 % w / w , or from about 25 % w / w to about 45 % w / w , or from about 28 % w / w to about 40 % w / w . in some other embodiments , the buffer is present in an amount of about 30 % w / w . in one embodiment of the invention , the pharmaceutical composition prepared by the methods of the invention comprises about 30 % w / w of sodium bicarbonate buffer . in some embodiments , the active ingredient contains an acid moiety , as described above . in some other embodiments , the active ingredient is a compound of formula ( a ), or a pharmaceutically acceptable salt thereof , as described above . in still a further embodiment , the active ingredient is a compound of formula ( i ), or a pharmaceutically acceptable salt thereof , as described above . in some embodiments , the active ingredient is a crystalline form of a compound of formula ( a ) or formula ( i ). in some other embodiments , the active ingredient is a crystalline form of a pharmaceutically acceptable salt of a compound of formula ( a ) or formula ( i ). some examples of pharmaceutically acceptable salts of the compounds of formula ( a ) or fointula ( 1 ) and crystalline forms thereof can be found in us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . in still a further embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ), or a crystalline form thereof . in another embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) monohydrate . in another embodiment , the active ingredient is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) polymorph form 2 , as described in us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . in some embodiments , the active ingredient is present in the amount from about 1 % w / w to about 60 % w / w . in some other embodiments , the active ingredient is present in the amount from about 1 % w / w to about 30 % w / w . in some other embodiments , the active ingredient is present in the amount from about 5 % w / w to about 25 % w / w , or from about 10 % w / w to about 20 % w / w , or from about 11 % w / w to about 18 % w / w , or from about 12 % w / w to about 16 % w / w . in some other embodiments , the active ingredient is present in the amount of about 10 % w / w , or about 11 % w / w , or about 12 % w / w , or about 13 % w / w , or about 14 % w / w , or about 15 % w / w , or about 16 % w / w . in some other embodiments , the active ingredient is present in the amount of about 13 . 6 % w / w . in another embodiment , the bulk composition comprises about 1 % w / w to about 60 % w / w of compound 1 , or a crystalline form thereof , about 10 % w / w to about 80 % w / w of sodium bicarbonate , about 10 % w / w to about 80 % w / w of microcrystalline cellulose , about 0 % w / w to about 5 % w / w of sodium stearyl fumarate , about 0 % w / w to about 5 % w / w of sodium lauryl sulfate , about 0 % w / w to about 20 % w / w of polyvinylpyrrolidone , and about 0 % w / w to about 20 % w / w of croscarmellose sodium . in another embodiment , the bulk composition comprises about 1 % w / w to about 30 % w / w of compound 1 , or a crystalline form thereof , about 30 % w / w to about 60 % w / w of sodium bicarbonate , and about 20 % w / w to about 60 % w / w of microcrystalline cellulose , about 1 % w / w to about 3 % w / w of sodium stearyl fumarate , about 0 % w / w to about 3 % w / w of sodium lauryl sulfate , about 0 % w / w to about 10 % w / w of polyvinylpyrrolidone , and about 0 % w / w to about 15 % w / w of croscarmellose sodium . in another embodiment , the bulk composition comprises about 10 % w / w to about 16 % w / w of compound 1 , or a crystalline form thereof , about 28 % w / w to about 40 % w / w of sodium bicarbonate , about 35 % w / w to about 45 % w / w of microcrystalline cellulose , about 1 % w / w to about 2 % w / w of sodium stearyl fumarate , about 1 % w / w to about 2 % w / w of sodium lauryl sulfate , about 3 % w / w to about 7 % w / w of polyvinylpyrrolidone , and about 5 % w / w to about 10 % w / w of croscarmellose sodium . in another embodiment , the bulk composition comprises about 13 . 6 % w / w of compound 1 , or a crystalline form thereof , about 30 . 0 % w / w of sodium bicarbonate , and about 40 . 4 % w / w of microcrystalline cellulose , about 1 . 0 % w / w of sodium stearyl fumarate , about 2 . 0 % w / w of sodium lauryl sulfate , about 5 . 0 % w / w of polyvinylpyrrolidone , and about 8 . 0 % w / w of croscarmellose sodium . in further embodiments , the invention provides pharmaceutical compositions that may be formulated into unit dosage forms . the expression “ unit dosage form ” as used herein refers to a physically discrete unit of agent appropriate for the subject to be treated . in some embodiments , the unit dosage form is a solid oral pharmaceutical dosage form . examples of solid oral pharmaceutical dosage forms include , but are not limited to tablets , capsules , pills , powders , and granules . in some embodiments , the solid oral pharmaceutical dosage form is a tablet . in some embodiments , the tablets are film - coated , or enterically coated , or both . in some other embodiments , the tablets are enterically coated . suitable excipients , including buffers , fillers , lubricants , surfactants , binders and disintegrants that may be used in the solid oral pharmaceutical dosage forms of the invention are described above . in some embodiments , the active ingredient of the solid oral pharmaceutical dosage form contains an acid moiety , as described above . in some other embodiments , the active ingredient is a compound of formula ( a ), a compound of formula ( i ), or a pharmaceutically acceptable salt of a compound of formula ( a ) or formula ( i ), as described above . in some embodiments , the active ingredient of the solid oral pharmaceutical dosage form is a crystalline form of a compound of formula ( a ) or formula ( i ). in some other embodiments , the active ingredient of the solid oral pharmaceutical dosage form is a crystalline form of a pharmaceutically acceptable salt of a compound of formula ( a ) or formula ( i ). some examples of pharmaceutically acceptable salts of the compounds of formula ( a ) or formula ( i ) and crystalline forms thereof can be found in us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . in still a further embodiment , the active ingredient of the solid oral pharmaceutical dosage form is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ), or a crystalline form thereof . in another embodiment , the active ingredient of the solid oral pharmaceutical dosage form is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) monohydrate . in another embodiment , the active ingredient of the solid oral pharmaceutical dosage form is sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ) polymorph form 2 , as described in us publication no . 2008 / 0167292 , and u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in their entirety . suitable materials that may be used as film coating include , but are not limited to , opadry ® ( hydroxy propyl methylcellulose peg ) ( colorcon , west point , pa . ), opadry ® ii ( polyvinyl alcohol , peg , talc , and titanium dioxide ), opadry ® fx , opadry ® amb , and mixtures thereof . in some embodiments , the film - coat material is opadry ®, opadry ® ii , or mixtures thereof . in other embodiments , the film - coat material is opadry ® ii . in some embodiments , the film - coat material is present in the solid oral pharmaceutical dosage form in an amount from about 0 % w / w to about 10 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the film - coat material is present in the solid oral pharmaceutical dosage form in an amount from about 0 % w / w to about 8 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the film - coat material is present in the solid oral pharmaceutical dosage form in an amount from about 0 % w / w to about 6 % w / w , or about 0 . 5 % w / w to 5 . 5 % w / w , or about 1 . 0 % w / w to 5 . 0 % w / w , or about 1 . 5 % w / w to 4 . 5 % w / w , or about 2 . 0 % w / w to 4 . 0 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the film - coat material is present in the solid oral pharmaceutical dosage form in an amount of about 3 . 6 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). suitable materials that may be used as enteric coating include , but are not limited to , acryl - eze ® ( methacrylic acid copolymer , talc , sls , titanium dioxide , sodium bicarbonate , silica , triethyl citrate ) ( colorcon , west point , pa . ), cellulose acetate phthalate ( cap ), methyl acrylate - methacrylic acid copolymers , cellulose acetate succinate , hydroxy propyl methyl cellulose phthalate , hydroxy propyl methyl cellulose acetate succinate ( hypromellose acetate succinate ), polyvinyl acetate phthalate ( pvap ), methyl methacrylate - methacrylic acid copolymers , and mixtures thereof . in some embodiments , the enteric - coat material is present in the solid oral pharmaceutical dosage form in an amount from about 0 % w / w to about 20 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the enteric - coat material is present in the solid oral pharmaceutical dosage form in an amount from about 0 % w / w to about 18 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the enteric - coat material is present in the solid oral pharmaceutical dosage fount in an amount from about 0 % w / w to about 15 % w / w , or about 5 % w / w to 13 % w / w , or about 7 % w / w to about 11 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in other embodiments , the enteric - coat material is present in the solid oral pharmaceutical dosage form in an amount of about 9 . 4 % w / w , wherein the total weight includes all the components of the coated tablet including the coating ( s ). in another embodiment , the solid oral pharmaceutical dosage form comprises about 1 % w / w to about 60 % w / w of compound 1 , or a crystalline form thereof , about 10 % w / w to about 80 % w / w of sodium bicarbonate , about 10 % w / w to about 80 % w / w of microcrystalline cellulose , about 0 % w / w to about 5 % w / w of sodium stearyl fumarate , about 0 % w / w to about 5 % w / w of sodium lauryl sulfate , about 0 % w / w to about 20 % w / w of polyvinylpyrrolidone , about 0 % w / w to about 20 % w / w of croscarmellose sodium , about 0 % w / w to about 10 % w / w of film coating , and about 0 % w / w to about 20 % w / w of enteric coating . in another embodiment , the solid oral pharmaceutical dosage form comprises about 1 % w / w to about 30 % w / w of compound 1 , or a crystalline form thereof , about 30 % w / w to about 60 % w / w of sodium bicarbonate , and about 20 % w / w to about 60 % w / w of microcrystalline cellulose , about 1 % w / w to about 3 % w / w of sodium stearyl fumarate , about 0 % w / w to about 3 % w / w of sodium lauryl sulfate , about 0 % w / w to about 10 % w / w of polyvinylpyrrolidone , about 0 % w / w to about 15 % w / w of croscarmellose sodium , about 05 % w / w to about 5 . 5 % w / w of film coating , and about 5 % w / w to about 13 % w / w of enteric coating . in another embodiment , the solid oral pharmaceutical dosage form comprises about 10 % w / w to about 16 % w / w of compound 1 , or a crystalline form thereof , about 28 % w / w to about 40 % w / w of sodium bicarbonate , about 35 % w / w to about 45 % w / w of microcrystalline cellulose , about 1 % w / w to about 2 % w / w of sodium stearyl fumarate , about 1 % w / w to about 2 % w / w of sodium lauryl sulfate , about 3 % w / w to about 7 % w / w of polyvinylpyrrolidone , about 5 % w / w to about 10 % w / w of croscarmellose sodium about 2 % w / w to about 4 % w / w of film coating , and about 7 % w / w to about 11 % w / w of enteric coating . in another embodiment , the solid oral pharmaceutical dosage form comprises about 11 . 9 % w / w of compound 1 , or a crystalline form thereof , about 26 . 1 % w / w of sodium bicarbonate , and about 35 . 1 % w / w of microcrystalline cellulose , about 0 . 9 % w / w of sodium stearyl fumarate , about 1 . 7 % w / w of sodium lauryl sulfate , about 4 . 4 % w / w of polyvinylpyrrolidone , about 7 . 0 % w / w of croscarmellose sodium , about 3 . 6 % w / w of opadry ® clear coating , and about 9 . 4 % w / w of acryl - eze ® white enteric coating , wherein the total weight includes all the components of the coated tablet including the coatings . the pharmaceutical compositions of the invention comprising compounds of formula ( a ), or pharmaceutically acceptable salts thereof , compounds of formula ( i ), or pharmaceutically acceptable salts thereof , and compound 1 , or crystalline forms thereof are particularly useful in therapeutic applications relating to mitotic kinase mediated diseases , disorders or conditions , particularly aurora kinase mediated diseases , disorders or conditions . inhibiting mitotic kinase activity may serve to treat a number of diseases , involving cell survival , proliferation , and migration , including cancer , as well as other cell - proliferative diseases . one aspect of the invention , therefore , provides methods for treating aurora kinase - mediated disorders by administering a therapeutically effective amount of the pharmaceutical composition of the invention . as used herein , the tetra “ aurora kinase - mediated disorder ” includes any disorder , disease or condition which is caused or characterized by an increase in aurora kinase expression or activity , or which requires aurora kinase activity . the term “ aurora kinase - mediated disorder ” also includes any disorder , disease or condition in which inhibition of aurora kinase activity is beneficial . aurora kinase - mediated disorders include proliferative disorders . non - limiting examples of proliferative disorders include chronic inflammatory proliferative disorders , e . g ., psoriasis and rheumatoid arthritis ; proliferative ocular disorders , e . g ., diabetic retinopathy ; benign proliferative disorders , e . g ., hemangiomas ; and cancer . non - limiting examples of cancer include colorectal cancer , ovarian cancer , breast cancer , gastric cancer , prostate cancer , and pancreatic cancer . the physical and chemical stability of the oral pharmaceutical dosage form may be tested in a conventional manner , for example , the measurement of dissolution or disintegration time , or moisture content , or assay for the active ingredient or degradation products after storage at different temperatures for different lengths of time . the pharmaceutical compositions , prepared according to the method of the present invention , may be administered using any amount effective for treating the disease . the exact amount required will vary from subject to subject , depending on the species , age , and general condition of the subject , the severity of the infection , the particular active ingredient , its mode of administration , and the like . the pharmaceutical compositions are preferably formulated in an oral pharmaceutical unit dosage form for ease of administration and uniformity of dosage . the expression “ unit dosage form ” as used herein refers to a physically discrete unit of agent appropriate for the subject to be treated . it will be understood , however , that the total daily usage of the pharmaceutical compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment . the specific effective dose level for any particular subject will depend upon a variety of factors including the disease being treated and the severity of the disease ; the activity of the specific compound employed ; the specific composition employed ; the age , body weight , general health , sex and diet of the subject ; the time of administration , and rate of excretion of the specific compound employed ; the duration of the treatment ; drugs used in combination or coincidental with the specific compound employed , and like factors well known in the medical arts . in some embodiments the unit dosage form comprises about 1 mg to about 250 mg of active ingredient . in some other embodiments the unit dosage form comprises about 5 mg to about 200 mg of active ingredient . in some other embodiments the unit dosage form comprises about 10 mg to about 150 mg of active ingredient . in still some other embodiments the unit dosage form comprises about 10 mg to about 100 mg of active ingredient . in order that this invention be more fully understood , the following preparative examples are set forth . these examples illustrate how to make or test specific compositions , and are not to be construed as limiting the scope of the invention in any way . sodium 4 -{[ 9 - chloro - 7 -( 2 - fluoro - 6 - methoxyphenyl )- 5h - pyrimido [ 5 , 4 - d ][ 2 ] benzazepin - 2 - yl ] amino }- 2 - methoxybenzoate ( compound 1 ), and crystalline forms thereof may be prepared according to synthetic methods described in us publication no . 2008 / 0167292 or u . s . application no . 61 / 306 , 047 , filed feb . 19 , 2010 , hereby incorporated by reference in its entirety . where compound 1 is used in the examples below , the term will be understood to refer to compound 1 , or a crystalline form thereof . examples of pharmaceutical compositions that may be prepared using the methods of the present invention are shown in the examples below . a 1 . 0 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 06 kg ) was screened and blended with microcrystalline cellulose ( 0 . 79 kg ) in a diosna p1 - 6 high shear wet granulator . polyvinylpyrrolidone ( 0 . 08 kg ) and croscarmellose sodium ( 0 . 08 kg ) were screened and added to the granulator . the granulating liquid ( water ) was sprayed at a predetermined spray rate of 50 g / minute using a peristaltic pump . once the end point was reached with an approximate moisture content of 38 . 5 % of the wet granulated material , the resulting wet granules were screened and subsequently dried using a gpcg - 1 fluid bed dryer . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . sodium bicarbonate ( 30 % w / w ), croscarmellose sodium ( 3 % w / w ) and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with composition as shown in table 4 . a 0 . 65 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 13 kg ) was screened and blended with microcrystalline cellulose ( 0 . 40 kg ) in a diosna p1 - 6 high shear wet granulator . sodium lauryl sulfate ( 0 . 02 kg ), polyvinylpyrrolidone ( 0 . 05 kg ), and croscarmellose sodium ( 0 . 05 kg ) were screened and added to the granulator . the granulating liquid ( water ) was sprayed at a predetermined spray rate of 35 g / minute using a peristaltic pump . once the end point was reached with an approximate moisture content of 37 . 5 % of the wet granulated material , the resulting wet granules were screened subsequently dried using a gpcg - 1 fluid bed dryer . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . sodium bicarbonate ( 30 % w / w ), croscarmellose sodium ( 3 % w / w ), and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with a composition as shown in table 5 . a 4 . 8 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 64 kg ) was screened through 14 mesh screen and blended with microcrystalline cellulose ( 1 . 95 kg ), sodium lauryl sulfate ( 0 . 1 kg ), polyvinylpyrrolidone ( 0 . 24 kg ), and croscarmellose sodium ( 0 . 24 kg ) in a pma25 / 65 high shear wet granulator . purified water was sprayed at a predetermined spray rate of 180 - 235 g / minute using a peristaltic pump . a total of 1 kg of purified water was sprayed in this process . once the end point was reached with an approximate moisture content of 25 % of the wet granulated material , the resulting wet granules were screened subsequently dried using a gpcg - 1 fluid bed dryer . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . sodium bicarbonate ( 30 % w / w ), croscarmellose sodium ( 3 % w / w ), and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with a composition as shown in table 5 . a 4 . 8 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 64 kg ) was screened through 14 mesh screen and blended with microcrystalline cellulose ( 1 . 95 kg ), sodium lauryl sulfate ( 0 . 1 kg ), polyvinylpyrrolidone ( 0 . 24 kg ), and croscarmellose sodium ( 0 . 24 kg ) in a pma25 / 65 high shear wet granulator . purified water was sprayed at a predetermined spray rate of 242 g / minute using a peristaltic pump . a total of 0 . 8 kg of purified water was sprayed in this process . wet massing was performed for 2 minutes after spraying the water in this example . once the end point was reached with an approximate moisture content of 20 % of the wet granulated material , the resulting wet granules were screened subsequently dried using a gpcg - 1 fluid bed dryer . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . sodium bicarbonate ( 30 % w / w ), croscarmellose sodium ( 3 % w / w ), and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with a composition as shown in table 5 . a 4 . 8 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 64 kg ) was screened through 14 mesh screen and blended with microcrystalline cellulose ( 1 . 95 kg ), sodium lauryl sulfate ( 0 . 1 kg ), polyvinylpyrrolidone ( 0 . 24 kg ), and croscarmellose sodium ( 0 . 24 kg ) in a pma25 / 65 high shear wet granulator . purified water was sprayed at a predetermined spray rate of 200 g / minute to 254 g / minute using a peristaltic pump . a total of 0 . 8 kg of purified water was sprayed in this process . once the end point was reached with an approximate moisture content of 20 % of the wet granulated material , the resulting wet granules were screened and subsequently dried using a gpcg - 1 fluid bed dryer . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . sodium bicarbonate ( 30 % w / w ), croscarmellose sodium ( 3 % w / w ), and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with a composition as shown in table 5 . the resulting final blended granules from example 5 were loaded into a piccola 10 station tablet press with 7 / 32 ″ standard round concave tooling . the granules were compressed to manufacture tablets having a total weight of 80 mg per tablet ( 10 mg dose of compound 1 ). the resulting tablets were coated with a first coat of opadry ® clear coating followed by a second coat of acryl - eze ® white enteric coating using a vector ldcs perforated pan coater . the composition of the resulting enterically coated tablets is shown below in table 6 . the resulting final blended granules from example 5 may also be used to form the tablet compositions shown below in tables 7 and 8 . a 1 . 0 kg batch granulation was manufactured by the following process . compound 1 ( 0 . 04 kg ) was screened and blended with microcrystalline cellulose ( 0 . 55 kg ), sodium bicarbonate ( 0 . 32 kg ) and croscarmellose sodium ( 0 . 05 kg ) in a 4 quart pk blender . the blended mixture was then transferred into a gpcg - 1 fluid bed granulator . polyvinylpyrrolidone ( 0 . 05 kg ) was mixed with water ( 0 . 3 kg ) to make up a binder solution . the binder solution was sprayed at a predetermined spray rate of 21 g / minute using a peristaltic pump . once the binder solution was all sprayed into the gpcg - 1 fluid bed granulator , the drying process continued in the gpcg - 1 fluid bed granulator until a predetermined product and exhaust temperature were obtained . the resulting dried granules were screened and weighed . based on the weight obtained , a calculation was performed to determine the appropriate amount of extra - granular components . croscarmellose sodium ( 3 % w / w ), and sodium stearyl fumarate ( 1 % w / w ) were then blended with the screened , dried granules to give a batch with composition as shown in table 9 . while we have described a number of embodiments of this invention , it is apparent that our basic examples may be altered to provide other embodiments , which utilize the compounds and methods of this invention . therefore , it will be appreciated that the scope of this invention is to be defined by the appended claims rather than by the specific embodiments , which have been represented by way of example .
this invention provides novel solid pharmaceutical compositions and processes for the bulk production of said compositions . this invention also provides methods of using the pharmaceutical compositions in the treatment of cancer .